Spero Therapeutics Slashes 39% of Workforce Following Phase 2 Antibiotic Trial Failure

Workforce Reduction:
Spero Therapeutics has laid off 39% of its employees in response to a phase 2 trial failure of its oral antibiotic candidate.

Cash Runway Extension:
The layoffs are intended to extend the company's cash runway to 2026.

Trial Failure:
An interim analysis revealed a double blow to the antibiotic candidate, leading to the significant workforce cut.

Impact:
The failure and subsequent layoffs highlight the challenges in developing new antibiotics and the financial pressures on biotech companies facing trial setbacks.